
NYSE:UNH
This summary was created by AI, based on 36 opinions in the last 12 months.
UnitedHealth Group Inc (UNH) has seen a tumultuous year, with many experts highlighting the volatility stemming from changes in leadership, regulatory pressures, and rising medical costs. Positive reviews point to regaining earnings power, especially with the return of the former CEO, who is expected to manage costs effectively and steer the company towards recovery. However, there are significant concerns about the impact of government regulations and Medicare adjustments, which could pressure margins and complicate growth prospects. The consensus reflects a blend of optimism for long-term recovery juxtaposed with caution due to ongoing industry challenges and political uncertainties. In summary, while there are indicators of potential upside, the unpredictable nature of healthcare reforms in the U.S. builds a case for cautious investment.
Yes. It was a top pick of his last spring. He doesn't think there will be much negative impact from Washington investigating their billing practices, though there remains headline risk. Fundamentals are improving, though they are paying out more for medical costs, which he hopes will normalize. It's trading below the market PE, when usually it trades above.
It is integral to the systematic delivery of health care across the U.S. and is a leader in well vertically integrated companies. There are some headwinds which he thinks will dissipate. He likes the longer term prospects and is seeing the development of per capita growth.
Buy 29 Hold 1 Sell 0
He bought some yesterday. Didn't change guidance. Q4 profitability was OK, though revenue was a bit light. Health insurance in US will continue to grow, it's a leader. Core holding for him. Great distribution system, so cost is less than peers. Trump administration will not nationalize healthcare.
Well run and uses AI a lot. It's an easy punching bag in the US for critics of the healthcare system. Health is always a political hot knife, but HC is the biggest employer in the US. Some disagree, but it's not in their interest to screw customers (by denying claims). He has been this all the way down.
Low beta, more conservative name. Very significant scale. Far ahead of peers with strong alignment of medical insurance, pharmacy benefits, and healthcare services. Aging demographics are key drivers of demand. Shares are 19% off their highs, an opportunity. 18x PE for 11% growth. Yield is 1.7%.
(Analysts’ price target is $641.46)The entire US health insurance group is embroiled in a controversy that was unfortunately set off by the murder of UNH, specifically talk about how claims are treated at UNH. These stocks are falling, but hang on and let this pass and see how different parties react. There will always be a place for health insurance companies in the US.
Down today, so an opportunity. The largest health insurer can do anything it wants under this presidency.